美麗田園醫療健康(02373.HK)斥800萬人幣購杭州三間生活美容門店
美麗田園醫療健康(02373.HK)公布,其子公司杭州美麗田園美容有限公司與杭州妍工房及其實際控制人簽署收購協議,以對價約800萬元人民幣收購杭州妍工房業務,共涉及3間生活美容門店,上述收購完成後,經重組後集團將持有相關業務項目公司100%的股權,並將業績併入集團的綜合財務報表。
該3間公司分別為杭州妍工房美容有限公司、杭州妍億蓓美容有限公司及杭州市上城區妍泰美容店。
公司認為杭州地區對集團具有戰略意義,並相信通過與杭州目標公司的協同效應和資源整合,交易將優化集團在杭州地區的網點佈局,補充會員體量,為集團整體收益的提升做出貢獻。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.